Autor(es): Ji Wen-yan,Lu Li,Lü Min,Miao Liang,Gao Ting,Huang Ruo-gang,Suo Luo-dan,Liu Dong-lei,Ma Rui,Yu Rui,Zhangzhu Jia-zi,Liu Wei-xiang,Zeng Yang,Li Xiao-mei,Wu Jiang

Resumo: To evaluate the safety and epidemiological effects on the first mass vaccination program, using the China-made A (H1N1) influenza vaccine. Descriptive epidemiology and cohort study design were used to assess the influenza A H1N1 vaccine on its safety and epidemiological effects. 95 244 subjects were immunized with A (H1N1) influenza vaccine. 193 adverse events were reported through AEFI Management System, with the Reported rates of AEFI as 2.03?. Most of the adverse events (137/193, 71.0%) happened during the first 24 hours after immunization was carried out. Of 81 adverse reactions confirmed to be related to immunization, with 78 (96.3%) showed mild reactions. No Guillain-Barre Syndrome related to vaccination was reported through the AEFI Management System. The epidemiological protection rate of A (H1N1) vaccine could reach 80.9% when the coverage was not considered. The A (H1N1) influenza vaccine showed a similar safety profile to seasonal flu vaccine. The vaccine demonstrated a good epidemiological effects against A (H1N1) influenza virus infection.

Imprenta: Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi, v. 31, n. 5, p. 481-484, 2010

Identificador do objeto digital: 10.3760 / cma.j.issn.0254-6450.2010.05.001

Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Viral infections ; Guillain-Barre Syndrome - virus ; Guillain-Barre Syndrome - Vaccine ; Guillain-Barre Syndrome - Epidemiology ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health

Data de publicação: 2010

INDICADORES

ACESSO